Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Catalent's Q2 Earnings Beat Street View, Lifts FY22 Guidance

Catalent Inc (NYSE:CTLT) has reported Q2 FY22 sales of $1.22 billion, +34% Y/Y as reported, or 35% in constant currency, edging out analysts' average expectation of $1.15 billion.

  • Adjusted EPS of $0.90, compared to $0.63 last year, surpassed the consensus of $0.83.
  • Adjusted EBITDA was $310 million, or a margin of 25.4%, compared to $224 million (24.5%) a year ago.
  • Biologics segment sales increased 57.9% (60% cc) to $638 million.
  • Softgel and Oral Technologies segment revenues of $329 million were up 33.2% (36% cc).
  • The Oral and Specialty Delivery segment's sales were $156 million, a decrease of -8.2% (-8% cc).
  • Clinical Supply Services segment revenues improved 6.5% (7% cc) to $99 million.
  • Related: FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report.
  • Guidance: For FY22, Catalent expects revenue of $4.74 billion - $4.86 billion, versus the consensus of $4.71 billion, and higher than prior guidance of $4.62 billion - $4.82 billion. 
  • It expects adjusted EBITDA of $1.25 billion - $1.30 billion, compared to $1. 225 billion - $1.295 billion expected earlier.
  • The Company forecasts adjusted net income of $650 million - $700 million, better than $630 million - $695 million anticipated earlier.
  • Price Action: CTLT shares closed at $103.93 on Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.